Ebola virus: Canadian researchers develop experimental vaccine that is said to be safe for humans
Canadian researchers in a clinical trial have developed a Ebola vaccine which is well-tolerated and showed no safety concerns
Toronto: Canadian researchers in a clinical trial have developed a vaccine for disease caused by Ebola virus.
The study found that the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) is well-tolerated and showed no safety concerns.
The rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebola virus.
Only mild to moderate side-effects were seen, with only three severe reactions, including headache, diarrhoea and fatigue, which were completely resolved, the researchers said.
Further, participants reported high-antibody levels in six months after the immunisation.
"The results of this trial were positive and very promising. All three dose levels of the rVSV Ebola vaccine were well-tolerated by participants, and no safety concerns were identified," said lead author May ElSherif, Canadian Centre for Vaccinology -- an integrated collaborative vaccine research centre in Nova Scotia.
Data from this trial and others indicated an optimum dose of 20 million plaque-forming unit (PFU) that will be assessed among people with compromised immune systems in areas where Ebola is endemic.
The 2013-2016 Ebola virus outbreak in West Africa was the most widespread in history.
There were some latest clusters of Ebola cases in Africa and more expected as survivors may still spread the virus to uninfected people, the researchers said.
For the trial, published in CMAJ (Canadian Medical Association Journal), the team involved 40 healthy people aged 18 to 65 years and looked at safety of the vaccine and the lowest dose required for an immune response after injection with one of three doses.
Given the ongoing presence of Ebola, "these facts underscore the importance of continuing efforts and collaborations that may ultimately lead to licensed Ebola vaccines that would protect humans and prevent or control outbreaks in the future," ElSherif added.
An experimental vaccine to prevent Ebola virus disease has been found to be well-tolerated and produced immune system responses in all 20 healthy adults who received it in a Phase 1 clinical trial, researchers report.
The cases marked the first known resurgence of the virus in West Africa since the 2016 epidemic that left more than 11,300 dead across the region
West Africa braces to combat first Ebola outbreak in five years as COVID-19 stretches limited health resources
Patients have been isolated and an investigation was ordered to determine the home villages of all who took part in the burial to carry out contact tracing, said head of National Agency for Health Security